Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01059201 · ClinicalTrials.gov registry record

Exome Sequencing in Autistic Spectrum Disorder

A clinical trial of Autism Spectrum Disorder and Autism, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

Completed
Registry status
322
Enrollment target
3
Study locations

NCT01059201: Completed study of Autism Spectrum Disorder and Autism, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

NCT01059201 is a study of Autism Spectrum Disorder and Autism that has completed, run by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The registered enrollment target is 322 participants, above the 134-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (140% higher). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01059201, a study of Autism Spectrum Disorder and Autism, has completed, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

COMPLETED
Registry status
322 participants
Enrollment target
3
Study locations

Study Summary

Background: * Research into the genetic causes of autism spectrum disorder (ASD) involves studies of the DNA of children with autism. New DNA sequencing technology allows researchers to study specific genes in search of genetic changes that may cause or contribute to ASD. Individuals who donated DNA to the Autism Genetic Resource Exchange may benefit from further study of their DNA samples with more advanced DNA sequencing technology. * The role of cholesterol in individuals with ASD is currently under investigation. Research has suggested that abnormal cholesterol levels in children with autism may be related to genetic mutations or changes in how cholesterol is regulated in the body. Objectives: \- To study existing blood samples of children with autism spectrum disorders to evaluate the relationship between genetic traits and cholesterol function. Eligibility: \- Children with ASD who donated blood samples to the Autism Genetic Resource Exchange. Design: * Parents/guardians of minor children with ASD will provide consent for further research to be performed on existing DNA samples in the Autism Genetic Research Exchange databank. Information from this research may be provided to the consenting parents/guardians on a case by case basis, as directed by the researchers.

Study Locations (3)

Maryland

  • Kennedy Krieger Institute - Baltimore
  • National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda

Ohio

  • Ohio State University - Columbus

Trial Details

FieldValue
Enrollment Target 322 participants
Start Date 2010-01-21
Est. Completion 2017-05-15

What the finished NCT01059201 record still lists

NCT01059201 is an observational study that tracks outcomes without assigning an intervention. The registered 322 participants enrollment target is mid-sized for trials with a published cap, above the 134-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (140% higher).

The record links to 3 conditions, with Autism Spectrum Disorder appearing as the primary indexed condition, and to 0 interventions.

NCT01059201 reports a single indexed study location in Maryland, Ohio.

Frequently Asked Questions

What is clinical trial NCT01059201 about?

NCT01059201 is a clinical study titled "Exome Sequencing in Autistic Spectrum Disorder". Background: * Research into the genetic causes of autism spectrum disorder (ASD) involves studies of the DNA of children with autism. New DNA sequencing technology allows researchers to study specific genes in search of genetic changes that may cause or contribute to ASD. Individuals who donated DN...

What is the current status of trial NCT01059201?

This trial is currently completed. The enrollment target is 322 participants. The study started on 2010-01-21. Estimated completion is 2017-05-15.

What conditions does trial NCT01059201 study?

This clinical trial studies the following conditions: Autism Spectrum Disorder, Autism, Autistic Disorder.

Who is sponsoring clinical trial NCT01059201?

This trial is sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), which has 305 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01059201 being conducted?

This trial has 3 study locations across Maryland, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Autism Spectrum Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01059201's enrollment target sits among peer trials

322 23rd of 224 higher than 202 of 224 other Autism Spectrum Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Autism Spectrum Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04090359 · 322 participants · Phase 4

    Dual Mobility Acetabular Cups in Revision TJA

  • NCT04924075 · 322 participants · Phase 2

    Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

  • NCT03715933 · 321 participants · Phase 1

    Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

  • NCT05922878 · 321 participants · Phase 2

    Study of ALTO-300 in MDD

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01059201, the US trial registry maintained by the National Library of Medicine. NCT01059201 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.